Renal Cell Carcinoma, Clear Cell
5
0
1
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
11 treatments under study, led by Bms986213 Relatlimabnivolumab Fdc
Research Leaders
13 sponsors active, led by Bristol-Myers Squibb
Related Conditions
Often studied with 9 related conditions
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 5 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (5)
A Clinical Study of Ivonescimab in Combination With Cadonilimab or Ipilimumab for Advanced Renal Cancer
A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC)
Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors
A Multimodal Predictive Recurrence Score for Patients With Clear Cell Renal Cell Carcinoma
Denosumab and Pembrolizumab in Clear Cell Renal Carcinoma
Research Network
Common Treatments
- Bms986213 Relatlimabnivolumab Fdc1
- Ivonescimab Dose Level 1 Combined With Cadonilimab1
- Ivonescimab Combined With Ipilimumab1
- Drugs Nivolumab1
- Ivonescimab1
Active Sponsors
- Bristol-Myers Squibb1
- Australian and New Zealand Urogenital and Prostate Cancer Trials Group1
- RenJi Hospital1
- M.D. Anderson Cancer Center1
- Summit Therapeutics1
Top Investigators
M.D. Anderson Cancer Center
Xencor, Inc.
Related Conditions
- Nonsmall Cell Lung Cancer Squamous Or Nonsquamous1
- Head And Neck Squamous Cell Carcinoma1
- Colorectal Cancer1
- Tnbc Triplenegative Breast Cancer1
- Melanoma Excluding Uveal Melanoma1